BVT Call 210 PGR 20.12.2024/ DE000VD3SAR9 /
6/28/2024 8:44:47 AM | Chg.+0.19 | Bid9:59:58 PM | Ask9:59:58 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.02EUR | +10.38% | - Bid Size: - |
- Ask Size: - |
Progressive Corporat... | 210.00 USD | 12/20/2024 | Call |
GlobeNewswire
6/28
Rocky Mountain Chocolate Factory Appoints Charles B. Arnold to Its Board of Directors and Audit Comm...
GlobeNewswire
6/28
KBio Announces FDA Clearance of IND Application for EV68-228-N for the Treatment of Acute Flaccid My...
GlobeNewswire
6/28
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle a...
GlobeNewswire
6/25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
6/24
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
6/24
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
6/24
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
6/13
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
6/12
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
6/12
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/11
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
6/11
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
6/10
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...
GlobeNewswire
6/10
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in...